Dr. Devarati Mitra, MD, PhD

Dr. Mitra practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Mitra's NPI, 1407260714, was assigned on June 13, 2014. Dr. Mitra graduated from Harvard Medical School in 2014. Dr. Mitra holds Texas license S1661.

Dr. Mitra's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Mitra's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mitra practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Mitra's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Mitra is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Mitra's licenses on file in 11 states: Texas, Florida, Arizona, Tennessee, Georgia, Louisiana, Mississippi, Washington, Alabama, Oklahoma and Massachusetts.

Dmand AI lists anal cancer radiation, bone cancer radiation, brain cancer radiation, colorectal cancer radiation and head & neck cancer radiation among the conditions Dr. Mitra treats.

CMS data shows 1,204 Medicare services from Dr. Mitra across 11 procedure codes in 2024, for 131 Medicare patients. Medicare paid $78,695 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 131 Medicare patients who saw Dr. Mitra in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have high blood pressure, and 73% have high cholesterol. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mitra's median patient age at 67, with 53% women.

In 2024, Dr. Mitra wrote 19 Medicare Part D claims for 15 patients. 95% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $51 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Mitra for performance year 2024, reported as part of a group. Dr. Mitra accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 71 papers to Dr. Mitra, published from 2012 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Melanoma, Sarcoma and Proto-Oncogene Proteins B-raf. Dr. Mitra has published most often in Int J Radiat Oncol Biol Phys. Dr. Mitra's most frequent co-authors are Ahsan S. Farooqi, MD, PhD, Andrew Justin Bishop, MD and Beverly Ashland Guadagnolo, MD, MPH.

Dmand AI links Dr. Mitra to 3 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Merkel Cell, Melanoma and Nevi and Melanomas. M.D. Anderson Cancer Center sponsors the most, 3.

Dr. Mitra graduated from Harvard Medical School in 2014.

Dr. Mitra is in network with 4 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 3. Check the plan with the practice before a visit.